AG 3433

Drug Profile

AG 3433

Latest Information Update: 21 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Agouron Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 21 Sep 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 22 Jun 2000 Warner-Lambert has merged with Pfizer
  • 10 Aug 1999 Two preclinical studies have been added to the pharmacokinetics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top